Compare ASTRAZENECA PHARMA with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs AUROBINDO PHARMA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA AUROBINDO PHARMA ASTRAZENECA PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 119.9 16.5 727.0% View Chart
P/BV x 35.1 3.4 1,038.2% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 ASTRAZENECA PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
AUROBINDO PHARMA
Mar-19
ASTRAZENECA PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,278830 154.0%   
Low Rs883527 167.4%   
Sales per share (Unadj.) Rs228.4333.9 68.4%  
Earnings per share (Unadj.) Rs10.440.4 25.7%  
Cash flow per share (Unadj.) Rs16.351.8 31.4%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs98.8237.1 41.7%  
Shares outstanding (eoy) m25.00585.91 4.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.72.0 232.7%   
Avg P/E ratio x104.216.8 619.9%  
P/CF ratio (eoy) x66.413.1 506.8%  
Price / Book Value ratio x10.92.9 382.1%  
Dividend payout %06.2 0.0%   
Avg Mkt Cap Rs m27,008397,569 6.8%   
No. of employees `0001.417.9 7.6%   
Total wages/salary Rs m1,53525,849 5.9%   
Avg. sales/employee Rs Th4,210.910,956.9 38.4%   
Avg. wages/employee Rs Th1,132.21,447.7 78.2%   
Avg. net profit/employee Rs Th191.11,324.3 14.4%   
INCOME DATA
Net Sales Rs m5,710195,636 2.9%  
Other income Rs m1231,553 7.9%   
Total revenues Rs m5,833197,189 3.0%   
Gross profit Rs m46339,519 1.2%  
Depreciation Rs m1476,680 2.2%   
Interest Rs m02,626 0.0%   
Profit before tax Rs m43831,767 1.4%   
Minority Interest Rs m027 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m1797,269 2.5%   
Profit after tax Rs m25923,645 1.1%  
Gross profit margin %8.120.2 40.1%  
Effective tax rate %40.822.9 178.5%   
Net profit margin %4.512.1 37.5%  
BALANCE SHEET DATA
Current assets Rs m3,209153,645 2.1%   
Current liabilities Rs m2,070120,429 1.7%   
Net working cap to sales %20.017.0 117.6%  
Current ratio x1.61.3 121.5%  
Inventory Days Days72135 53.5%  
Debtors Days Days3564 54.8%  
Net fixed assets Rs m790103,909 0.8%   
Share capital Rs m50586 8.5%   
"Free" reserves Rs m2,419138,322 1.7%   
Net worth Rs m2,469138,908 1.8%   
Long term debt Rs m01,800 0.0%   
Total assets Rs m4,605264,544 1.7%  
Interest coverage xNM13.1-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.20.7 167.7%   
Return on assets %5.69.9 56.7%  
Return on equity %10.517.0 61.6%  
Return on capital %17.723.8 74.4%  
Exports to sales %049.6 0.0%   
Imports to sales %018.8 0.0%   
Exports (fob) Rs mNA97,091 0.0%   
Imports (cif) Rs mNA36,741 0.0%   
Fx inflow Rs m30097,316 0.3%   
Fx outflow Rs m2,01540,589 5.0%   
Net fx Rs m-1,71556,727 -3.0%   
CASH FLOW
From Operations Rs m8816,220 0.5%  
From Investments Rs m-94-28,768 0.3%  
From Financial Activity Rs mNA19,191 0.0%  
Net Cashflow Rs m-66,656 -0.1%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 8.0 3.8%  
FIIs % 15.7 27.7 56.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.2 89.2%  
Shareholders   12,856 69,601 18.5%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  UNICHEM LAB  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 345 Points Lower; Auto and IT Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure in the last hour of trading and ended their session on a negative note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jul 8, 2020 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - PANACEA BIOTECH COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS